Expression of Mismatch Repair Proteins in Merkel Cell Carcinoma

Simple Summary Merkel cell carcinoma (MCC) is a rare and highly malignant skin cancer with neuroendocrine differentiation. About 80% are Merkel cell polyomavirus (MCPyV) positive. The aim of this work was to immunohistochemically investigate the expression of mismatch repair proteins (MSH2, MSH6, MLH1, and PMS2) in MCC (n = 56). In a second step, tumors with a low expression were tested for microsatellite instability. Microsatellite instability in MCC could have an impact on immune checkpoint inhibitor therapy (ICI) outcome. This study showed a significant association between low expression of mismatch repair proteins and a negative MCPyV status. Microsatellite instability was detected in only one case. Future studies will establish whether this subset of MCC patients respond better to ICI. Abstract We aimed to assess for the first time the mismatch repair (MMR) protein expression in Merkel cell carcinoma (MCC). Immunohistochemistry was performed for MLH1, MSH2, MSH6, and PMS2 on patients’ tumor tissue (n = 56), including neighbored healthy control tissue. In cases with low-level MMR expression (<10th percentile), we performed multiplex PCR in combination with high-resolution capillary electrophoresis in order to confirm microsatellite instability (MSI). Microscopic evaluation revealed a high median expression for all MMR proteins studied (91.6–96.3%). However, six patients (56/10.7%) had low-level MLH1 expression, six (55/10.9%) had low-level MSH2 expression, five (56/8.9%) had low-level MSH6 expression, and six (54/11.1%) had low-level PMS2 expression. Together, we observed nine (56/16.1%) patients who had low-level MMR expression of at least one protein. Of the patients with low-level MMR expression, MSI evaluation was possible in five cases, revealing one case with high-level MSI. In all MMR proteins assessed, low-level expression was significantly (p = 0.0004 to p < 0.0001) associated with a negative Merkel cell polyomavirus (MCPyV) status. However, the expression profiles of the MMR proteins did not correlate with clinical outcome measures such as disease relapse or death (p > 0.05). MCC appears to be a malignancy characterized by low-level MMR rather than completely deficient MMR in a subset of cases, predominantly affecting MCPyV-negative tumors. Future studies will establish whether this subset of MCC patients respond better to immune checkpoint inhibitor therapy.

[1]  M. Sabel,et al.  Immunotherapy for Merkel cell carcinoma , 2021, Journal of surgical oncology.

[2]  Mojun Zhu,et al.  Management of Non-Colorectal Digestive Cancers with Microsatellite Instability , 2021, Cancers.

[3]  J. Decaprio,et al.  Predictors of immunotherapy benefit in Merkel cell carcinoma , 2020, OncoTarget.

[4]  J. Becker,et al.  Patched 1 expression in Merkel cell carcinoma , 2020, Journal of dermatology (Print).

[5]  G. Banna,et al.  Diagnostic test assessment. Validation study of an alternative system to detect microsatellite instability in colorectal carcinoma , 2020, Pathologica.

[6]  Hui Luo,et al.  Microsatellite instability: a review of what the oncologist should know , 2020, Cancer Cell International.

[7]  G. Pellacani,et al.  Immunohistochemical mismatch repair proteins expression as a tool to predict the melanoma immunotherapy response , 2019, Molecular and clinical oncology.

[8]  M. Edelman,et al.  Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors , 2019, Advances in Therapy.

[9]  E. Slodkowska,et al.  PD‐L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type, of the uterine cervix , 2019, Histopathology.

[10]  E. V. Van Allen,et al.  Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients? , 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[11]  Ahmet Zehir,et al.  Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response , 2019, Science.

[12]  J. Becker,et al.  S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – update 2018 , 2019, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[13]  L. Roncati.  Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma. , 2019, Acta dermatovenerologica Croatica : ADC.

[14]  G. Mills,et al.  ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade , 2018, Nature Medicine.

[15]  C. Fottner,et al.  Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia , 2018, Oncology Research and Treatment.

[16]  J. Becker,et al.  Merkel cell carcinoma , 2017, Nature Reviews Disease Primers.

[17]  C. Berking,et al.  Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe , 2017, Oncotarget.

[18]  Muhammad M. Edhi,et al.  Mismatch repair deficiency screening in colorectal carcinoma by a four-antibody immunohistochemical panel in Pakistani population and its correlation with histopathological parameters , 2017, World Journal of Surgical Oncology.

[19]  J. Becker,et al.  Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma , 2017, Future oncology.

[20]  J. Kopecký,et al.  Microsatellite instability in melanoma: a comprehensive review , 2016, Melanoma research.

[21]  S. Richman.  Deficient mismatch repair: Read all about it (Review) , 2015, International journal of oncology.

[22]  P. Marchetti,et al.  High expression of the mismatch repair protein MSH6 is associated with poor patient survival in melanoma. , 2014, American journal of clinical pathology.

[23]  B. Stolte,et al.  No evidence for a causal role of Merkel cell polyomavirus in keratoacanthoma. , 2012, Journal of the American Academy of Dermatology.

[24]  J. Becker,et al.  Merkel cell carcinoma: recent insights and new treatment options , 2012, Current opinion in oncology.

[25]  M. Kloor,et al.  Absence of mismatch repair deficiency-related microsatellite instability in non-melanoma skin cancer. , 2012, The Journal of investigative dermatology.

[26]  P. Karran,et al.  Expression of DNA mismatch repair proteins and MSH2 polymorphisms in nonmelanoma skin cancers of organ transplant recipients , 2009, The British journal of dermatology.

[27]  H. Pfister,et al.  Merkel Cell Polyomavirus DNA in Persons without Merkel Cell Carcinoma , 2009, Emerging infectious diseases.

[28]  H. Joensuu,et al.  Clinical factors associated with Merkel cell polyomavirus infection in Merkel cell carcinoma. , 2009, Journal of the National Cancer Institute.

[29]  E. Patsouris,et al.  Mutations of microsatellite instability target genes in sporadic basal cell carcinomas. , 2007, Pathology, research and practice.

[30]  C. Cordon-Cardo,et al.  Application of in situ hybridization probes for MLH-1 and MSH-2 in tissue microarrays of paraffin-embedded malignant melanomas: correlation with immunohistochemistry and tumor stage. , 2004, Human pathology.

[31]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.